^
Association details:
| Biomarker: | IDH2 mutation + NTRK3 fusion |
|---|---|
| Cancer: | Astrocytoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
ADULT GLIOMA: IDH-MUTANT ASTROCYTOMA….Recurrent or Progressive Disease WHO grade 2, KPS ≥60...Useful in Certain Circumstances...NTRK gene fusion tumors...Larotrectinib
